Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6. https://doi.org/10.1038/s41572-020-00240-3

Article  PubMed  Google Scholar 

Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76:681–693. https://doi.org/10.1016/j.jhep.2021.11.018

Article  PubMed  Google Scholar 

Xie D, Shi J, Zhou J et al (2023) Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Chinese perspective. Clin Mol Hepatol 29:206–216. https://doi.org/10.3350/cmh.2022.0402

Article  PubMed  Google Scholar 

Peng Z, Fan W, Zhu B et al (2023) Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol 41:117–127. https://doi.org/10.1200/JCO.22.00392

Article  CAS  PubMed  Google Scholar 

Kudo M, Ueshima K, Ikeda M et al (2020) Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 69:1492–1501. https://doi.org/10.1136/gutjnl-2019-318934

Article  PubMed  Google Scholar 

Tian Y, Lei Y, Fu Y et al (2022) Molecular mechanisms of resistance to tyrosine kinase inhibitors associated with hepatocellular carcinoma. Curr Cancer Drug Targets 22:454–462. https://doi.org/10.2174/1568009622666220330151725

Article  CAS  PubMed  Google Scholar 

Kalasekar SM, VanSant-Webb CH, Evason KJ (2021) Intratumor heterogeneity in hepatocellular carcinoma: challenges and opportunities. Cancers 13:5524. https://doi.org/10.3390/cancers13215524

Article  CAS  PubMed Central  PubMed  Google Scholar 

Gillmore R, Stuart S, Kirkwood A et al (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55:1309–1316. https://doi.org/10.1016/j.jhep.2011.03.007

Article  PubMed  Google Scholar 

Man KF, Ma S (2022) Mechanisms of resistance to tyrosine kinase inhibitors in liver cancer stem cells and potential therapeutic approaches. Essays Biochem 66:371–386. https://doi.org/10.1042/EBC20220001

Article  CAS  PubMed  Google Scholar 

Eun JW, Yoon JH, Ahn HR et al (2023) Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun (Lond) 43:455–479. https://doi.org/10.1002/cac2.12414

Article  PubMed  Google Scholar 

Xue M, Wu Y, Fan W et al (2020) Prognostic value of TP53 mutation for transcatheter arterial chemoembolization failure/refractoriness in HBV-related advanced hepatocellular carcinoma. Cancer Res Treat 52:925–937. https://doi.org/10.4143/crt.2019.533

Article  CAS  PubMed Central  PubMed  Google Scholar 

Huang K, Wu Y, Fan W et al (2023) Identification of BRD7 by whole-exome sequencing as a predictor for intermediate-stage hepatocellular carcinoma in patients undergoing TACE. J Cancer Res Clin Oncol 149:11247–11261. https://doi.org/10.1007/s00432-023-04883-z

Article  CAS  PubMed  Google Scholar 

Jin H, Shi Y, Lv Y et al (2021) EGFR activation limits the response of liver cancer to lenvatinib. Nature 595:730–734. https://doi.org/10.1038/s41586-021-03741-7

Article  CAS  PubMed  Google Scholar 

Chen Y, Liu Q, Chen Z et al (2019) PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. J Exp Clin Cancer Res 38:193. https://doi.org/10.1186/s13046-019-1192-1

Article  PubMed Central  PubMed  Google Scholar 

Gabbia D, De Martin S (2023) Tumor mutational burden for predicting prognosis and therapy outcome of hepatocellular carcinoma. Int J Mol Sci 24:3441. https://doi.org/10.3390/ijms24043441

Article  CAS  PubMed Central  PubMed  Google Scholar 

Sung JY, Park DW, Lee SH (2022) High tumor mutation burden is associated with poor clinical outcome in EGFR-mutated lung adenocarcinomas treated with targeted therapy. Biomedicines 10:2109. https://doi.org/10.3390/biomedicines10092109

Article  CAS  PubMed Central  PubMed  Google Scholar 

Offin M, Rizvi H, Tenet M et al (2019) Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin Cancer Res 25:1063–1069. https://doi.org/10.1158/1078-0432.CCR-18-1102

Article  CAS  PubMed  Google Scholar 

Wang Z, Wang X, Xu Y et al (2022) Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. BMC Med 20:133. https://doi.org/10.1186/s12916-022-02327-y

Article  CAS  PubMed Central  PubMed  Google Scholar 

Bera K, Braman N, Gupta A et al (2022) Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol 19:132–146. https://doi.org/10.1038/s41571-021-00560-7

Article  CAS  PubMed  Google Scholar 

Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749–762. https://doi.org/10.1038/nrclinonc.2017.141

Article  PubMed  Google Scholar 

Ji GW, Zhu FP, Xu Q et al (2019) Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: a multi-institutional study. EBioMedicine 50:156–165. https://doi.org/10.1016/j.ebiom.2019.10.057

Article  PubMed Central  PubMed  Google Scholar 

Zhang H, Guo D, Liu H et al (2022) MRI-based radiomics models to discriminate hepatocellular carcinoma and non-hepatocellular carcinoma in LR-M according to LI-RADS version 2018. Diagnostics (Basel) 12:1043. https://doi.org/10.3390/diagnostics12051043

Article  CAS  PubMed  Google Scholar 

Brancato V, Garbino N, Salvatore M et al (2022) MRI-based radiomic features help identify lesions and predict histopathological grade of hepatocellular carcinoma. Diagnostics (Basel) 12:1085. https://doi.org/10.3390/diagnostics12051085

Article  PubMed  Google Scholar 

Xu X, Zhang HL, Liu QP et al (2019) Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol 70:1133–1144. https://doi.org/10.1016/j.jhep.2019.02.023

Article  PubMed  Google Scholar 

Ren Q, Zhu P, Li C et al (2022) Pretreatment computed tomography-based machine learning models to predict outcomes in hepatocellular carcinoma patients who received combined treatment of trans-arterial chemoembolization and tyrosine kinase inhibitor. Front Bioeng Biotechnol 10:872044. https://doi.org/10.3389/fbioe.2022.872044

Article  PubMed Central  PubMed  Google Scholar 

Liu K, Zheng X, Lu D et al (2024) A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram. Radiol Med 129:14–28. https://doi.org/10.1007/s11547-023-01736-0

Article  PubMed  Google Scholar 

Llovet JM, Lencioni R (2020) mRECIST for HCC: Performance and novel refinements. J Hepatol 72(2):288–306. https://doi.org/10.1016/j.jhep.2019.09.026

Article  PubMed  Google Scholar 

Van Griethuysen JJM, Fedorov A, Parmar C et al (2017) Computational radiomics system to decode the radiographic phenotype. Cancer Res 77:e104–e107. https://doi.org/10.1158/0008-5472.CAN-17-0339

Article  CAS  PubMed Central  PubMed  Google Scholar 

Wang DD, Zhang JF, Zhang LH et al (2023) Clinical-radiomics predictors to identify the suitability of transarterial chemoemb